In the RATIFY trial where 717 patients with FLT3-ITD and/or TKD mutant AML were randomized to receive midostaurin or placebo in addition to standard intensive chemotherapy, OS was significantly longer with HR of 0.78 and p value of 0.00917. The gene discussed is FLT3; the disease is acute myeloid leukemia.